Esophageal carcinoma: The unusual variants

M. D. Lieberman, Dido Franceschi, B. Marsan, M. Burt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2% of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small- cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54% and 9% for mucoepidermoid carcinoma (median survival, 5 months) and 16% and 0% for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86% of patients in whom recurrence developed after esophagectomy. Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy.

Original languageEnglish
Pages (from-to)1138-1146
Number of pages9
JournalJournal of Thoracic and Cardiovascular Surgery
Volume108
Issue number6
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Mucoepidermoid Carcinoma
Carcinoma
Esophagectomy
Survival
Carcinosarcoma
Adenoids
Drug Therapy
Adenoid Cystic Carcinoma
Group Psychotherapy
Esophagus
Radiotherapy
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Lieberman, M. D., Franceschi, D., Marsan, B., & Burt, M. (1994). Esophageal carcinoma: The unusual variants. Journal of Thoracic and Cardiovascular Surgery, 108(6), 1138-1146.

Esophageal carcinoma : The unusual variants. / Lieberman, M. D.; Franceschi, Dido; Marsan, B.; Burt, M.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 108, No. 6, 01.01.1994, p. 1138-1146.

Research output: Contribution to journalArticle

Lieberman, MD, Franceschi, D, Marsan, B & Burt, M 1994, 'Esophageal carcinoma: The unusual variants', Journal of Thoracic and Cardiovascular Surgery, vol. 108, no. 6, pp. 1138-1146.
Lieberman, M. D. ; Franceschi, Dido ; Marsan, B. ; Burt, M. / Esophageal carcinoma : The unusual variants. In: Journal of Thoracic and Cardiovascular Surgery. 1994 ; Vol. 108, No. 6. pp. 1138-1146.
@article{b3cda3e1fc2c4e2cbccc65553fa66121,
title = "Esophageal carcinoma: The unusual variants",
abstract = "The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2{\%} of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small- cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54{\%} and 9{\%} for mucoepidermoid carcinoma (median survival, 5 months) and 16{\%} and 0{\%} for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86{\%} of patients in whom recurrence developed after esophagectomy. Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy.",
author = "Lieberman, {M. D.} and Dido Franceschi and B. Marsan and M. Burt",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "108",
pages = "1138--1146",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Esophageal carcinoma

T2 - The unusual variants

AU - Lieberman, M. D.

AU - Franceschi, Dido

AU - Marsan, B.

AU - Burt, M.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2% of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small- cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54% and 9% for mucoepidermoid carcinoma (median survival, 5 months) and 16% and 0% for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86% of patients in whom recurrence developed after esophagectomy. Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy.

AB - The clinical behavior and response to therapy of rare histologic variants of esophageal carcinoma are unclear. To evaluate the results of therapy in this group the records of 29 patients treated between 1949 and 1991 with primary rare histologic variants of esophageal carcinoma were retrospectively reviewed. This group represented 1.2% of 2454 cases of esophageal carcinoma treated between 1949 and 1991 and included mucoepidermoid (n = 14), small- cell (n = 12), adenoid cystic (n = 2), and carcinosarcoma (n = 1) carcinomas. Treatment for localized disease consisted of esophagectomy in five of seven patients with mucoepidermoid carcinoma, two of six patients with small-cell carcinoma, two of two patients with adenoid cystic carcinoma, and one of one patient with carcinosarcoma. Patients with stage IV mucoepidermoid carcinoma were treated predominately with radiation therapy (5/7). The majority of small cell carcinomas were treated with multiagent chemotherapy (10/12). The 1- and 3-year disease-specific survivals were 54% and 9% for mucoepidermoid carcinoma (median survival, 5 months) and 16% and 0% for small-cell carcinoma (median survival, 7 months), respectively. Patients with stage III mucoepidermoid carcinoma (median survival, 20.5 months) compared with those with stage III small-cell carcinoma (median survival, 6.2 months) had a significantly longer duration of survival (p < 0.05). Distant disease was present in 86% of patients in whom recurrence developed after esophagectomy. Esophagectomy is standard therapy for localized carcinomas of the esophagus. Small-cell carcinoma appears to be a more aggressive variant of carcinoma and is most commonly treated with chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027944231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027944231&partnerID=8YFLogxK

M3 - Article

C2 - 7983884

AN - SCOPUS:0027944231

VL - 108

SP - 1138

EP - 1146

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -